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In 2008, the world market experienced a troubled period
with respect to reliability of the product heparin. In the
United States and Europe, lots of non-fractionated heparin
were fraudulently contaminated with oversulfated
chondroitin, which resulted in death of hundreds of
patients. Brazil was also affected by the problem of heparin,
but in other way.
In early 2008, after the abrupt withdrawal from the market
of non-fractioned endovenous heparin of the Roche
laboratory (Liquemine), the Brazilian Society of
Cardiovascular Surgery (BSCVS) began to receive alarming
increase in queries from cardiac surgeons from around the
country about the appearance of complications with the
use of other brands of heparin available in the domestic
market. These reported complications mostly involved
increased postoperative bleeding and appearance of
vasoplegic syndrome.
The mobilization of BSCVS began by contact with the
Roche laboratory, that reaffirmed the decision to cease the
production of endovenous Liquemine. This brand of heparin
(manufactured from the intestinal mucosa of pigs) was used
by almost all the services of Cardiovascular Surgery of the
country and had great reliability. At the same time, the
National Health Surveillance Agency (ANVISA) was
notified and the appropriate actions were requested.
Then, the BSCVS contacted directly the pharmaceutical
companies that market the non-fractioned heparin sodium
in Brazil. Eurofarm and Bérgamo laboratories manufacture
injectable heparin sodium from raw material (bovine
intestinal mucosa) provided by national companies.
The analysis of these products, performed at the
Connective Tissue Laboratory of the Federal University of
Rio de Janeiro, and additional tests performed in
laboratories of the Federal University of Paraná and Federal
University of Santa Maria, Rio Grande do Sul, showed no
evidence of contamination by oversulfated chondroitin in
the product analyzed. It was noted that the quantity of low
molecular weight heparin met the reference product
specifications.
However, based on this analysis, it was shown clear
difference in potency of action between the non-
fractionated heparins from different origins, bovine and
porcine – the latter, as the case of Liquemine. The porcine
heparins have greater power of action than  the bovine
ones, with need for dose adjustment and more accurate
monitoring when there is change of the product, which
may explain the complications observed when the
Liquemine was withdrawn from the market [1].
It became obvious that, although safe for use, the
heparins made from bovine intestine are not the ideal choice
for cardiovascular surgery, unlike those heparins made with
pig intestine. Due to the difference in power between the
non-fractionated heparins both of bovine and porcine
origin, the recommendation from BSCVS was that a more
rigorous testing of activated coagulation time (ACT) during
heart surgery should be performed in order to ensure that
ideal levels of anticoagulation were being achieved.
It was agreed that the pharmaceutical companies, with
the support of the ANVISA and BSCVS, would develop the
heparin derived from intestinal mucosa of pigs - similar to
the product Liquemine that was withdrawn from the market.
Four national pharmaceutical companies - Blausiegel,
Bérgamo, Eurofarma and Cristália - developed the product
heparin, derived from pig intestines. Under quality tests,
these porcine heparins showed chemical structure and
activity similar to the product Liquemine as study performed
at the Connective Tissue Laboratory of the Federal
University of Rio de Janeiro, since the raw materials for
domestic industries comes from the same chinese
pharmaceutical company that provided such material for
the company Roche. The Chinese pharmaceutical were
inspected by the Food and Drug Administration (FDA) and
the ANVISA, that certified the laboratories with the GMP/
BPF Good Manufacturing Practices certification.
After long and detailed agreement with ANVISA and
national pharmaceutical companies that market heparin in
Brazil, BSCVS started a clinical study with those porcine
heparins to be marketed in Brazil, with a protocol extensively
discussed between the Parties, to ensure quality and
standardization of the product to be introduced in the
national market.
The clinical study started is being performed in only
one center to ensure uniformity of the procedure (Federal
University of Campinas - UNICAMP) and will provide clinical
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and scientific informations that may be relevant to the
knowledge of the product’s action, as well as its
neutralization by protamine. It is a phase III study, whose
primary objective is to verify, by means of randomized, open,
parallel, and comparative study, the efficacy and safety of
non-fractioned heparin sodium of porcine origin in patients
undergoing heart surgery using cardiopulmonary bypass,
by controlling of hemostasis during and after surgery, based
on measurements of coagulation markers, such as ACT,
activated partial thromboplastin time (aPTT) and anti-factor
Xa assay on the bioavailable heparin and blood loss. The
secondary objective of this study is to evaluate the average
dose of heparin sodium used in surgery and its relation
with the dose of protamine and the need for transfusions
of blood and blood products during and after the procedure.
Also,  a secondary objective of this study is to evaluate
the safety of the use of heparin in relation to type, incidence
and rate of adverse events observed during the study
period.
In agreement with the Adib Jatene Foundation, the
devices for measurement of ACT and the substrate used in
such devices will also be assessed so we can have a proper
comparison between advanced methods of evaluation of
the coagulation and anticoagulation and simple method
(ACT) routinely used in operations with cardiopulmonary
bypass in Brazilian hospitals.
Finally, the BSCVS would like to emphasize the sense of
responsibility and professionalism demonstrated by
national pharmaceutical companies, who have undertaken
all efforts to develop and supply the national market with
porcine non-fractionated heparins for specific use in
cardiovascular surgery, eliminating the trouble left by
withdrawal of the product Liquemine from the market by
the Roche company. Moreover, the action of ANVISA with
competent and dedicated professionals who worked closely
with the BSCVS and domestic industry, promoted conditions
for the rapid return of the product on the market. We also
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emphasize the great reception of the BSCVS by ANVISA,
that put its trust in our society so that the protocol may be
developed and established, showing a partnership that will
certainly be beneficial not only in the field of heparins but
in others on which BSCVS, as authentic representative of
Brazilian cardiovascular surgeons, may assist in the
qualification of all supplies we used.
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